Current Report Filing (8-k)
03 9월 2022 - 6:16AM
Edgar (US Regulatory)
0001772028
false
0001772028
2022-08-31
2022-08-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 31, 2022
SCOPUS BIOPHARMA INC.
(Exact name of registrant as specified in
its charter)
Delaware |
|
001-39788 |
|
82-1248020 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
420 Lexington Avenue, Suite 300
New York, New York 10170
(Address of principal executive offices)
(212) 479-2513
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section
12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.001 par value |
|
SCPS |
|
The Nasdaq Stock Market LLC (Nasdaq Global Market) |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 3.01 Notice of Delisting or Failure to Satisfy
a Continued Listing Rule or Standard; Transfer of Listing.
As previously reported
on a Form 8-K filed on March 4, 2022, Scopus BioPharma Inc. (the “Company”) received a deficiency notification letter from
the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) on March 3, 2022 indicating that the Company was
not in compliance with Nasdaq Listing Rule 5450(b)(2)(C), which requires listed securities to maintain a minimum Market Value of Publicly
Held Shares of $15,000,000 (the “MVPHS Requirement”).
Also, as previously
disclosed, the Company had scheduled a hearing with the Nasdaq Hearings Panel (the “Panel”) at which the Panel would
consider the Company’s plan for regaining compliance with Nasdaq listing standards, including the MVPHS Requirement. Such
hearing occurred on August 25, 2022. Subsequent to such hearing, on August 31, 2022, the Company received an additional letter from
Nasdaq because the Company had not regained compliance with the MVPHS Requirement as of August 30, 2022. In anticipation of the
expiration of such cure period, the Company addressed the MVPHS Requirement as part of its compliance plan during its hearing. The
Panel will consider this matter in their decision regarding the Company’s continued listing on Nasdaq. Until the Panel renders
a decision on the Company’s appeal, this delisting action will be stayed and the Company’s common stock will continue to
be listed on Nasdaq.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
SCOPUS BIOPHARMA INC. |
|
|
Dated: September 2, 2022 |
By: |
/s/ Joshua R. Lamstein |
|
|
Joshua R. Lamstein |
|
|
Chairman |
Scopus BioPharma (NASDAQ:SCPS)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Scopus BioPharma (NASDAQ:SCPS)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024